Bachem Holding AG (BANB) AI Stock Analysis

• Market Cap: CHF5.09B
• Dividend Yield: 1.43%
• Average Volume (3M): 109.83K
• Price to Earnings (P/E): 37.6
• Beta (1Y): 1.03
• Revenue Growth: 17.34%
• EPS Growth: 18.15%
• Country: CH
• Employees: 2,207
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): 0.67
• Shares Outstanding: 75,000,000
• 10 Day Avg. Volume: 97,857
• 30 Day Avg. Volume: 109,830
• PEG Ratio: 5.42
• Price to Book (P/B): 3.12
• Price to Sales (P/S): 7.17
• P/FCF Ratio: -31.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF82.67
• Price Target Upside: 21.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: CHF80.00 ▲(17.91% Upside)

The score is primarily driven by strong financial performance (growth, profitability, and low leverage), partially offset by negative free cash flow from high capital spending. Technicals are supportive due to a strong uptrend, but overbought momentum readings raise near-term risk. Valuation is a meaningful headwind given the high P/E and modest dividend yield.

Positive Factors

Revenue & Margins

Sustained revenue growth and stable gross/net margins indicate durable demand and operational efficiency. Consistent EBIT/EBITDA margins support reinvestment capacity, fund R&D and capacity expansion, and underpin long-term profitability across business cycles.

Balance Sheet Strength

Low leverage and a high equity ratio provide financial flexibility for multi-year capex and strategic investments, reduce refinancing risk, and increase resilience to sector swings, supporting durable funding for growth initiatives and customer contracts.

Customer Partnerships & R&D

Long-term pharma partnerships deliver recurring, multi-year revenue visibility while R&D investment sustains product differentiation in peptides. Together these create structural competitive advantage and support continued higher-margin proprietary and contract work.

Negative Factors

Negative Free Cash Flow

Persistent negative free cash flow from heavy capex reduces retained liquidity and limits flexibility for dividends or opportunistic investments. Over several quarters this can force external financing or slower organic growth if capex fails to generate expected returns.

Capital Intensity / Equity-Funded Growth

Rapid asset growth funded mainly through equity reflects capital-intensive expansion which can dilute returns on equity and raise fixed-cost commitments. Higher capital intensity increases execution risk and extends payback periods for invested projects.

Concentration in Peptides & Pharma Clients

A focused business model centered on peptides and pharmaceutical clients concentrates revenue exposure. This increases sensitivity to shifts in client programs, regulatory setbacks or competitive entrants, limiting diversification and raising medium-term demand risk.

Bachem Holding AG Business Overview & Revenue Model

Company Description

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

How the Company Makes Money

Bachem generates revenue primarily through the production and sale of peptides and related services. Its revenue model is built around two key streams: the custom synthesis of peptides for clients, which includes tailored development and production services, and the sale of proprietary products, which are marketed under the Bachem brand. The company benefits from long-term partnerships with major pharmaceutical companies, providing a stable customer base and ongoing projects. Additionally, Bachem's investment in research and development allows it to innovate and expand its product offerings, which helps sustain and grow its revenue. The global demand for peptides in therapeutics and the rise of biotechnology further contribute to its earnings potential.

Bachem Holding AG Financial Statement Overview

Summary

Strong income statement performance (revenue growth, stable gross margin, healthy net margins, and strong EBIT/EBITDA margins) and a solid balance sheet with low leverage and a high equity ratio. Cash flow is a mild constraint due to recently negative free cash flow driven by high capital expenditures, despite strong operating cash flow.

Income Statement

Bachem Holding AG has shown a strong revenue growth rate with revenues increasing consistently year over year. The gross profit margin is stable, indicating good control over production costs. Net profit margins are healthy, supported by increasing net income over the past few years. EBIT and EBITDA margins are strong, showcasing efficient operations. The company has demonstrated solid growth and profitability in the medical pharmaceuticals sector.

Balance Sheet

The company maintains a low debt-to-equity ratio, reflecting low leverage and financial stability. The return on equity is robust, indicating effective use of equity to generate profits. The equity ratio is high, underscoring a strong capital structure. Bachem has increased its total assets significantly, primarily funded by equity, which reduces potential risks associated with high leverage.

Cash Flow

Bachem Holding AG exhibits strong operating cash flow relative to net income, indicating effective cash generation from operations. However, the free cash flow has been negative recently due to high capital expenditures, which could limit liquidity in the short term. Despite this, the company's investment in growth seems to be strategically driven.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	677.93M	605.26M	577.32M	531.74M	503.23M	402.00M
Gross Profit	211.69M	182.56M	176.96M	171.28M	166.73M	128.91M
EBITDA	190.52M	178.76M	163.28M	160.54M	156.47M	122.58M
Net Income	134.19M	120.25M	111.86M	100.68M	114.68M	78.06M
Balance Sheet
Total Assets	1.91B	1.92B	1.68B	1.38B	1.30B	710.88M
Cash, Cash Equivalents and Short-Term Investments	29.14M	95.20M	298.53M	268.43M	442.36M	23.50M
Total Debt	60.87M	290.00K	401.00K	691.00K	20.86M	107.55M
Total Liabilities	550.82M	531.88M	362.36M	214.21M	177.50M	235.17M
Stockholders Equity	1.36B	1.39B	1.32B	1.17B	1.12B	475.71M
Cash Flow
Free Cash Flow	-118.94M	-138.30M	-18.54M	-49.76M	-19.66M	45.53M
Operating Cash Flow	144.66M	146.32M	249.86M	92.59M	97.16M	114.63M
Investing Cash Flow	-172.39M	-148.88M	-170.81M	-63.17M	-469.13M	-69.31M
Financing Cash Flow	-5.30M	-61.26M	48.69M	-86.93M	437.58M	-42.66M

Bachem Holding AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 67.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Positive. The current price of 67.85 is below the 20-day moving average (MA) of 67.93, above the 50-day MA of 59.79, and above the 200-day MA of 58.30, indicating a neutral trend. The MACD of 2.75 indicates Positive momentum. The RSI at 56.23 is Neutral, neither overbought nor oversold. The STOCH value of 13.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BANB.

Bachem Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BANB	75 Outperform	CHF5.09B	37.60	10.07%	1.43%	17.34%	18.15%
SFZN	74 Outperform	CHF4.37B	27.32	15.79%	0.51%	0.77%	16.70%
YPSN	70 Outperform	CHF4.10B	21.28	27.15%	0.67%	27.63%	160.67%
GALE	70 Outperform	CHF4.96B	25.22	―	2.36%	5.84%	8.57%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
PPGN	61 Neutral	CHF883.59M	-26.98	―	―	12.03%	-19.29%
LONN	56 Neutral	CHF35.94B	38.51	―	0.75%	5.93%	29.83%

Bachem Holding AG Corporate Events

Bachem Appoints Anne-Kathrin Stoller as New CEO

Bachem Holding AG has announced the appointment of Anne-Kathrin Stoller as the new CEO, effective January 1, 2026. Stoller, who has been with the company since 2006 and previously led Bachem Americas, succeeds Thomas Meier, who has significantly contributed to the company’s growth and innovation in the pharmaceutical industry. This leadership change is expected to continue Bachem’s successful trajectory as a globally leading developer and manufacturer of peptides and oligonucleotides.

The most recent analyst rating on (CH:BANB) stock is a Hold with a CHF61.00 price target. To see the full list of analyst forecasts on Bachem Holding AG stock, see the CH:BANB Stock Forecast page.